Antibody drug conjugate: the “biological missile” for targeted cancer therapy

Zhiwen Fu,Shijun Li,Sifei Han,Chen Shi,Yu Zhang

DOI: https://doi.org/10.1038/s41392-022-00947-7

IF: 39.3

2022-03-22

Signal Transduction and Targeted Therapy

Abstract:Abstract Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to achieve accurate and efficient elimination of cancer cells, which has become one of the hotspots for the research and development of anticancer drugs. Since the first ADC, Mylotarg ® (gemtuzumab ozogamicin), was approved in 2000 by the US Food and Drug Administration (FDA), there have been 14 ADCs received market approval so far worldwide. Moreover, over 100 ADC candidates have been investigated in clinical stages at present. This kind of new anti-cancer drugs, known as “biological missiles”, is leading a new era of targeted cancer therapy. Herein, we conducted a review of the history and general mechanism of action of ADCs, and then briefly discussed the molecular aspects of key components of ADCs and the mechanisms by which these key factors influence the activities of ADCs. Moreover, we also reviewed the approved ADCs and other promising candidates in phase-3 clinical trials and discuss the current challenges and future perspectives for the development of next generations, which provide insights for the research and development of novel cancer therapeutics using ADCs.

biochemistry & molecular biology,cell biology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to improve the targeting and effectiveness of cancer treatment while reducing side effects on normal tissues. Specifically, the paper focuses on Antibody - Drug Conjugates (ADCs), a new - generation anticancer drug that combines the highly specific targeting ability of monoclonal antibodies and the powerful killing effect of cytotoxic drugs. By reviewing the history of ADCs, their mechanism of action, and the molecular aspects of their key components, the paper aims to explore how to overcome current challenges by optimizing the design of ADCs and look forward to future development directions.

The paper mentions that since the first ADC drug, Mylotarg®, was approved by the US Food and Drug Administration (FDA) in 2000, 14 ADC drugs have been approved in the global market so far, and more than 100 ADC candidate drugs are in the clinical trial stage. These new anticancer drugs, known as "biological missiles", are leading a new era of cancer - targeted therapy. However, the research and development of ADCs still face some challenges, such as improving drug stability, enhancing targeting accuracy, and reducing non - targeted toxicity. The paper also discusses currently approved ADC drugs and other promising candidate drugs in Phase III clinical trials, as well as the challenges and prospects for the future development of ADCs.